Cannabis stocks are getting more and more attention from Wall Street these days, and Aurora Cannabis Inc ACB received its first coverage from Stifel on Thursday.
The Analyst
Stifel analyst W. Andrew Carter initiated coverage of Aurora with a Hold rating and a C$10 ($7.47) price target.
The Thesis
Despite impressive growth numbers projected in the next several years, Carter said Aurora’s international medical-use growth opportunities are limited outside of Canada and Germany.
“We are cautious on Aurora in the near-term given the company's reliance on the capital markets to execute upon its near-term business plans, the lack of a definitive strategy for entering the U.S. market, and we believe the slower development of the global medical opportunity will yield downside versus consensus estimates,” he wrote in a note.
Need more cannabis news? Check out all of our coverage here.
For now, Carter said Aurora has an enviable position as the No. 2 Canadian cannabis producer behind top Stifel pick Canopy Growth Corp CGC. He isn't convinced Aurora management fully appreciates the level of investment that will be required to defend that position as the market grows.
Aurora has also yet to secure partnerships with a global consumer or pharmaceutical company. However, the addition of investor Nelson Peltz as a strategic advisor should help remedy the situation, according to Carter.
Carter said Aurora’s valuation has upside only if it can maintain its Canadian market leadership position and its industry-leading margins over time. The company will also need to demonstrate it can be profitable.
Price Action
Aurora shares traded lower by 3 percent to $7.48 at time of publication Thursday.
Related Links:
Stifel: Canopy Growth Is The 'Best Investable Opportunity' In Cannabis
Analyst Likes Tilray In The Long Run, But Says Stock Is Overvalued Right Now
Photo courtesy of Aurora Cannabis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.